^
    Back
    Association details:
    Biomarker:PECAM1 underexpression
    Cancer:Renal Cell Carcinoma
    Drug:sunitinib (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Bosn J Basic Med Sci
    Title:

    Prognostic and predictive significance of VEGF, CD31, and Ang-1 in patients with metastatic clear cell renal cell carcinoma treated with first-line sunitinib

    Published date:
    06/08/2022
    Excerpt:
    The study included 35 mccRCC patients who were treated with first-line sunitinib in period between 2009 and 2019….Those with low tumor CD31 expression had a longer median DFS than patients with high tumor CD31 expression (p=0.019).
    DOI:
    10.17305/bjbms.2022.7675